## Background: Neuroblastomas often acquire sustained drug resistance during therapy. sensitivities to carboplatin, etoposide, or melphalan were determined for 18 neuroblastoma cell lines; eight were sensitive and ten were resistant. as p53 mutations are rare in neuroblastomas studied at diagnosis,
Low frequency of the p53 gene mutations in neuroblastoma
β Scribed by Gaku Hosoi; Junichi Hara; Takayuki Okamura; Yuko Osugi; Shigehiko Ishihara; Masahiro Fukuzawa; Akira Okada; Shintaro Okada; Akio Tawa
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 589 KB
- Volume
- 73
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Mutational analysis of the pl6ICDKN2 gene was conducted by direct sequencing of the whole coding sequence (exom 1-3 and flanking splicing sites) in 21 esophageal squamous-cell carcinomas and 3 adenocarcinomas from a high-incidence area of Italy. Two inactivating mutations were found in exon I of the
Neuroblastoma is one of the most frequent tumors in infancy. We analyzed 26 neuroblastomas, two ganglioneuromas, and a neuroblastoma metastasis for mutations and homozygous deletions of the p16 (or MTS1 or CDKN2) gene by means of the polymerase chain reaction (PCR) in combination with the single-str
Transgenic mice deficient for the p53 gene were reported to frequently develop angiosarcoma (AS), suggesting that alterations in the gene are associated with tumorigenesis of AS. However, little is known about genetic changes, including p53 gene alterations, in human AS because of its rarity. We ana